[The efficacy and safety of telbivudine in korean patients with chronic hepatitis B]
- PMID: 18159148
- DOI: 10.3350/kjhep.2007.13.4.503
[The efficacy and safety of telbivudine in korean patients with chronic hepatitis B]
Abstract
Background and aims: Telbivudine is an L-nucleoside analogue with potent antiviral activity against hepatitis B virus (HBV). Clinical trials have shown that telbivudine is more potent than lamivudine for suppressing virus.
Methods: A total 101 Korean patients among 1,367 patients who participated in the phase III GLOBE trial were randomized in this study. All 101 HBeAg positive or HBeAg negative patients were assigned to treatment with 600 mg of telbivudine or 100 mg of lamivudine once daily. The primary efficacy endpoint (the "therapeutic response") was defined as suppression of the serum HBV DNA to less than 5 log10 copies/mL coupled with either normalization of the serum alanine aminotransferase level or loss of HBeAg. The secondary endpoints included the histologic response, serum HBV DNA reduction, serum alanine aminotransferase normalization and HBeAg loss for the HBeAg positive patients. This analysis includes the data collected at 52 weeks of treatment.
Results: Fifty four of 101 patients were assigned to telbivudine treatment and 47 patients were assigned to lamivudine treatment. At week 52, significantly more patients who were treated with telbivudine than those treated with lamivudine had a therapeutic response (83% vs 62%, respectively, P=0.017), their mean serum HBV DNA levels were more reduced (6.6 vs 5.6 log10 copies/mL, respectively, P=0.027), and they more often achieved PCR-undetectable levels of serum HBV DNA (74% vs 34%, P<0.0001). No virologic resistance to telbivudine was detected (0% vs 18%, respectively, P=0.001). Telbivudine was well tolerated and it had a safety profile comparable to lamivudine.
Conclusions: Patients treated with telbivudine achieved earlier and more profound viral suppression than those treated with lamivudine.
Similar articles
-
Telbivudine versus lamivudine in patients with chronic hepatitis B.N Engl J Med. 2007 Dec 20;357(25):2576-88. doi: 10.1056/NEJMoa066422. N Engl J Med. 2007. PMID: 18094378 Clinical Trial.
-
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.Gastroenterology. 2009 Feb;136(2):486-95. doi: 10.1053/j.gastro.2008.10.026. Epub 2008 Nov 1. Gastroenterology. 2009. PMID: 19027013 Clinical Trial.
-
Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.Hepatology. 2008 Feb;47(2):447-54. doi: 10.1002/hep.22075. Hepatology. 2008. PMID: 18080339 Clinical Trial.
-
Telbivudine.Drugs. 2007;67(13):1917-29. doi: 10.2165/00003495-200767130-00011. Drugs. 2007. PMID: 17722961 Review.
-
Telbivudine in the treatment of chronic hepatitis B.Adv Ther. 2009 Feb;26(2):155-69. doi: 10.1007/s12325-009-0004-y. Epub 2009 Feb 18. Adv Ther. 2009. PMID: 19225726 Review.
Cited by
-
Carbohydrate-based drugs launched during 2000-2021.Acta Pharm Sin B. 2022 Oct;12(10):3783-3821. doi: 10.1016/j.apsb.2022.05.020. Epub 2022 May 23. Acta Pharm Sin B. 2022. PMID: 36213536 Free PMC article. Review.
-
Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at week 24.BMC Gastroenterol. 2012 Dec 13;12:178. doi: 10.1186/1471-230X-12-178. BMC Gastroenterol. 2012. PMID: 23234302 Free PMC article. Clinical Trial.
-
Telbivudine: a review of its use in compensated chronic hepatitis B.Drugs. 2010 Oct 1;70(14):1857-83. doi: 10.2165/11204330-000000000-00000. Drugs. 2010. PMID: 20836578 Review.
-
Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B.Gut Liver. 2011 Sep;5(3):278-87. doi: 10.5009/gnl.2011.5.3.278. Epub 2011 Aug 18. Gut Liver. 2011. PMID: 21927654 Free PMC article.